These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11563407)

  • 1. Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects.
    Ding PY; Chu KM; Hu OY; Huang GM; Jeng JJ; Chang A; Delaney CL; MacAskill M; Yang BC; Jemal M; Smith R; Liao WC
    J Clin Pharmacol; 1999 Feb; 39(2):155-60. PubMed ID: 11563407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
    O'Grady P; Yee KF; Lins R; Mangold B
    Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
    Kostis JB; Garland WT; Delaney C; Norton J; Liao WC
    Clin Pharmacol Ther; 1995 Dec; 58(6):660-5. PubMed ID: 8529331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
    Gehr TW; Sica DA; Grasela DM; Duchin KL
    Eur J Clin Pharmacol; 1993; 45(5):431-6. PubMed ID: 8112372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration.
    Hu OY; Ding PY; Huang CS; Hwang GM; Chu KM
    J Clin Pharmacol; 1997 Sep; 37(9):834-40. PubMed ID: 9549638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
    Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B
    Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive pharmacodynamics of fosinopril in patients with congestive heart failure.
    Ford NF; Natarajan C; Fulmor IE; Smith RA; Hui KK
    J Clin Pharmacol; 1995 Aug; 35(8):785-93. PubMed ID: 8522635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
    Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA
    J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients.
    Gehr TW; Sica DA; Grasela DM; Fakhry I; Davis J; Duchin KL
    Eur J Clin Pharmacol; 1991; 41(2):165-9. PubMed ID: 1835932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment.
    Ford NF; Lasseter KC; Van Harken DR; Hammett JL; Raymond R; Manning J
    J Clin Pharmacol; 1995 Feb; 35(2):145-50. PubMed ID: 7751424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction.
    Uderman HD; Much DR; Brennan J; Delaney CL; Morgenthien EA; Weaver J; Stouffer BC; Chang SY; VanHarken D; Liao W
    Ann Pharmacother; 1999 May; 33(5):525-30. PubMed ID: 10369612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W; Boekens H; Waitzinger J; Miller U
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosinopril. Clinical pharmacokinetics and clinical potential.
    Shionoiri H; Naruse M; Minamisawa K; Ueda S; Himeno H; Hiroto S; Takasaki I
    Clin Pharmacokinet; 1997 Jun; 32(6):460-80. PubMed ID: 9195116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma.
    Cui S; Feng F; Ma M; Liu H; Chen Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jul; 854(1-2):143-51. PubMed ID: 17482898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
    Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA
    Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of fosinopril sodium in healthy subjects.
    Singhvi SM; Duchin KL; Morrison RA; Willard DA; Everett DW; Frantz M
    Br J Clin Pharmacol; 1988 Jan; 25(1):9-15. PubMed ID: 2967089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.